it seems there is means tested assistance for people on co-pay plans where their insure will not cover the cost or the full cost
hxxps://www.fruzaqla.com/ |
How many pay the full US price?
Won’t all the insurers/medicaid have significant discounts? |
A couple of recent bits:
(Published: 3:04pm, 29 Nov, 2023) “Fruquintinib, which will be marketed as Fruzaqla in the US by Tokyo-based Takeda Pharmaceutical Company, will also face a price bump similar to that of Toripalimab. A box of 21 pills each containing 5mg of the drug is sold in China for around 7,500 yuan (US$1,050), according to Chinese medical news site Medical Valley. Its US wholesale price will be US$25,200 for the same amount of medication, according to a Takeda prescribing document, putting it at 24 times the cost in China”
(Published: 7:00am, 28 Nov, 2023) “HutchMed (China), in which Hong Kong conglomerate CK Hutchison Holdings holds a major stake, is poised to market its self-developed cancer drug “fruquintinib” in Japan and Europe, according to a top executive. |
well the previous precedence continues, get a major drug approval (in this case a blockbuster $1.2bn+ in annual sales) and the share price dives!
At least short positions are radically lower than they were a few months ago
Hopefully we will get Gastric Cancer approval in China soon and Savolitinib NDA submission in the U.S. in early 2024
Great progress, which continues to accelerate. |
The DB session will be more interesting today, esp the questions, although it is late breaking news so how much new information they are willing to say is likely to be limited.
The obvious questions are when do they expect EU and JPN approvals, what are the milestone payments for these events and further details of the pricing in US - that may be too early or not their call. |
Perhaps today's Deutsche Bank ADR Virtual Investor presentation will help change the share price direction after the news?
HUTCHMED (China) Ltd. (Nasdaq/AIM: HCM | HKEX: 13)
11/09/2023 8:30PM - 9:00PM |
yes, we did it! and just like the day Frquintinib was approved in China, the share price dropped.... |
M&G have closed their entire short position in HK |
Let's hope the trend continues! The PDUFA news is getting closer and closer. Would be wonderful if we make it past 400p in the not too distant future. |
Well that's a 52 week intraday high this morning,an 18 month high in fact.This stock makes cryptocurrencies look like steady eddies. |
only 7 weeks until PDUFA |
lovely! we also have confirmation that the FDA has completed their inspection of the new factory |
RNS just dropped: "HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan...Alongside our partner Takeda, we are pleased to take this key step towards bringing fruquintinib to patients in Japan,” |
I assume they will hit the clinical development milestones in the corporate presentation….as they can reasonably predict when there will be news.
The remaining 2023 news that I am interested in is the FDA approval decision, also I think we can expect news of a Takeda Fruq Gastric Cancer trial in Japan and Korea as they are potentially large markets behind China for that treatment.
Further price moving news would be a new partnership for Suru or one of the new candidates going to enter approval (Sovlep/Amdiz)…;in theory these could happen at any time…..I think they need another deal in the next 12m to demonstrate the Takeda deal is not a one off…..I would like it to be IPSEN or Takeda to deepen these relationships. |
Two bits of news today.
Looking a touch better here over the last few days re: share price. Hope the trend continues. |
Thanks for sharing. Need to find some cash over the next 6 months to buy more. Excellent pipeline. |
New TD Research note |
Only poitics in the way.
At the end of the day the money will always win. |
And the close 2 years ago to the day was 578p! |
Trinity Delta in my inbox today: HUTCHMED’s clearly articulated strategy is delivering, with consistent clinical and commercial execution marking its continuing transition from a development stage company into a profitable commercial organisation. Growth in Oncology/ Immunology revenues, defined investment priorities, and a global partnering strategy should all contribute to achieving a FY25 breakeven target. HUTCHMED aims to expand its marketed portfolio of oncology drugs in China from three to six or seven by FY25, addressing blood disorders as well as solid tumours. First global launch of an in-house product, by partner Takeda, could occur in 2024, subject to a positive FDA approval decision in November. Our updated HUTCHMED valuation is $5.74bn ($32.95 per ADS), £4.78bn and HK$44.75n (549p or HK$51.40 per share). |
It may, at last, be a decent week for HCM: HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, August 29, 2023: HUTCHMED (China) Limited (“HUTCHMEDR21;) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to savolitinib for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction (“GEJ”) adenocarcinoma patients with mesenchymal epithelial transition factor (“MET”) amplification who have failed at least two lines of standard therapies. |
Up nearly 3% in HK. With luck it will be a better week in London when the market opens again tomorrow. |
some old malaise with Hutchmed, can any news impact the shareprice. Positive news and barely anything happens, negative news and the price plummets. |
Hopefully a good week for HCM incoming:
21st August 2023 - HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
EDIT - Hmm..... Perhaps not! Down nearly 2.6% in HK. HCM is just completely out of favour at present :-( |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
